Summit surges after AstraZeneca makes $2 billion equity investment

By Reuters News

** Shares of Summit Therapeutics SMMT.O up 18% at $18.2 in extended trading

** AstraZeneca AZN.L will make a $2 billion equity investment in Summit through convertible preferred shares

** Says investment is convertible into common stock at $18.36 per share, representing a premium to the day's closing price

** Co and AstraZeneca entered into a clinical collaboration to evaluate ivonescimab in combination with AstraZeneca's sonesitatug vedotin in gastrointestinal cancers

** Says it plans to evaluate ivonescimab with additional AstraZeneca cancer medicines, including antibody-drug conjugates

** Co says AstraZeneca's investment is expected to close by the end of the week, subject to customary conditions

** Up to last close, SMMT down 11.5% YTD

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk